Although these reports show initial promise, the currently available data are limited by small sample sizes, short treatment durations, lack of dose comparisons, and lack of short-term or long-term follow-up data
Semaglutide is a GLP-1 receptor agonist used to manage Type 2 diabetes and facilitate weight loss in individuals with obesity or overweight-related health conditions
It is also recommended to eat smaller, light, and bland meals, eat slowly, and avoid or limit alcohol consumption
It is preparation
It can improve insulin sensitivity, reduce fasting blood sugar levels, and lead to favorable changes in lipid profiles
Generally speaking, most of these products are not approved by the Therapeutic Goods Administration